1. Effects of simvastatin and rosuvastatin on RAS protein, matrix metalloproteinases and NF-κB in lung cancer and in normal pulmonary tissues.
- Author
-
Falcone, D., Gallelli, L., Di Virgilio, A., Tucci, L., Scaramuzzino, M., Terracciano, R., Pelaia, G., and Savino, R.
- Subjects
- *
PHARMACODYNAMICS , *SIMVASTATIN , *ROSUVASTATIN , *RAS proteins , *MATRIX metalloproteinases , *NF-kappa B , *LUNG cancer treatment , *THORACIC surgery , *GENE expression - Abstract
Objectives In this study, we have evaluated effects of 24-hour treatments with simvastatin or rosuvastatin on RAS protein, NF-κB and MMP expression in LC tissues obtained from 12 patients undergoing thoracic surgery. Materials and methods Normal and lung tumour tissues obtained from each sample were exposed to simvastatin (2.5-30 μ m) or rosuvastatin (1.25-30 μ m) and western blot analysis was then performed. Results We documented increased expression of proteins, MMP-2, MMP-9 and NF-κB-p65 in LC tissues, with respect to normal tissues ( P < 0.01). In the malignant tissues, simvastatin and rosuvastatin significantly ( P < 0.01) and dose-dependently reduced RAS protein, MMP-2/9 and NF-κB-p65 expression. Conclusions In conclusion, our results suggest that simvastatin and rosuvastatin could play a role in LC treatment by modulation of RAS protein, MMP-2/9 and NF-κB-p65. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF